



Dual Protect™ the world's only
antiviral condom

Australian Olympic Team taking Dual Protect™ VivaGel® Condoms to Rio

Melbourne, Australia; 16 May 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) and Ansell Limited (ASX: ANN) today proudly announce that the Australian Olympic team will be provided with antiviral Dual Protect™ VivaGel® condoms for the upcoming Olympic Games in Rio de Janeiro.

Dual Protect™ is the world's only antiviral condom, which is currently marketed by Ansell in Australia. While the physical barrier of the condom provides primary protection, the condom lubricant contains VivaGel®, an antiviral agent that has been proven in laboratory studies to inactivate HIV, HSV (genital herpes) and HPV (human papillomavirus), which are viruses that cause sexually transmitted infections (STIs).

Starpharma has also recently announced that the antiviral active, VivaGel®, showed near-complete antiviral protection against Zika virus in laboratory studies at levels significantly below the concentration in the Dual Protect™ condom. It is now known that Zika virus can be sexually transmitted.

VivaGel® is an Australian innovation developed by Starpharma, who has teamed up with Ansell to create the Dual Protect™ condom. This world-first innovation, also developed and first available in Australia, is currently in the process of being rolled-out to other countries around the world.

“Starpharma is delighted to play a role in supporting Australian athletes as they compete on the world-stage at the Olympic Games in Rio,” said Starpharma Chief Executive Officer, Dr Jackie Fairley. “Given sexual transmission of Zika virus is of increasing importance the potent activity of Starpharma’s VivaGel® against Zika could prove very significant.”

“As a global leader in protection solutions, Ansell is proud to support the Australian Olympic team during the Olympic Games in Brazil,” said Jeyan Heper, President and General Manager, Sexual Wellness Global Business Unit at Ansell.

“Ansell’s mission is to provide innovative solutions for safety, well-being and peace of mind, no matter who or where you are, and our LifeStyles® Dual Protect™ condoms, developed in cooperation with Starpharma, combines a high-quality condom with patented anti-viral technology.”

The Chef de Mission of the 2016 Australian Olympic Team, Kitty Chiller said “the health and wellbeing of the Team comes first and our association with Starpharma will provide extra protection for everyone on the Team, and is a common sense approach to a very serious problem we are facing in Rio”.

For more information on Dual Protect™ VivaGel® condoms, see:
<http://www.ansellcondoms.com.au/products/lifestyles-dual-protect-condoms>

For more information on VivaGel®, see:
http://www.starpharma.com/the_vivagel_condom

For personal use only

ABOUT STARPHARMA

Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's lead products are based on VivaGel® (SPL7013, astodimer sodium), a proprietary dendrimer which has antimicrobial properties. Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries, Inc., to market a value-added, VivaGel® condom. Okamoto is the market leader for condoms sold in Japan, which is the world's second largest condom market. VivaGel® formulated as a water based gel and delivered vaginally now also has EU regulatory approval for topical treatment and rapid relief of bacterial vaginosis (BV) and is under clinical development for the prevention of recurrent BV.

In the wider pharmaceutical field, Starpharma has both partnered and internal programs in Drug Delivery. A number of dendrimer-enhanced, or DEP® versions of existing drugs are under development, including DEP® docetaxel. AstraZeneca has signed a multi-product license with Starpharma for the use of its DEP® drug delivery platform in the development and commercialisation of an AstraZeneca oncology compound, with potential for follow on compounds directed at a defined family of targets.

For more information please visit: www.starpharma.com

About Ansell

Ansell is a world leader in providing superior health and safety protection solutions that enhance human well-being. With operations in North America, Latin America/Caribbean, EMEA and Asia, Ansell employs 15,000 people worldwide and holds leading positions in the personal protective equipment and medical gloves market, as well as in the sexual health and well-being category worldwide. Ansell operates in four main business segments: Medical, Industrial, Single Use and Sexual Wellness. Information on Ansell and its products can be found at www.ansell.com. #AnsellProtects



® and ™ are trademarks owned by Ansell Limited or one of its affiliates. © 2016 Ansell Limited. All Rights Reserved.

FOR FURTHER INFORMATION

Media:

Buchan Consulting
Rebecca Wilson
Mob: +61 417 382 391
rwilson@buchanwe.com.au
Arthur Chan
+61 2 9237 2805
achan@buchanwe.com.au

Starpharma:

Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary

+61 3 8532 2704
ruth.dimmack@starpharma.com
investor.relations@starpharma.com

Ansell:

Tom Paoella, Global Communications
+1 732 345-2167
tom.paoella@ansell.com

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.